EndoChoice Announces Health Canada License for Fuse Endoscopy System in Canada
Full Spectrum Endoscopy Cleared for Marketing
ATLANTA, Jan. 14, 2014 /PRNewswire/ — EndoChoice(®) today announced the company has received a license from Health Canada to market its innovative Fuse(TM) Full Spectrum Endoscopy(TM) system in Canada. The Health Canada license means Fuse will be the first endoscopy system available with expanded viewing capabilities to reach Canadian patients. Endoscopes are thin flexible tubes with imaging capabilities that doctors use to view the upper and lower GI tracts of their patients.
The Fuse endoscopy system is comprised of colonoscopes and gastroscopes with multiple imagers enabling doctors to see more of the GI tract for diagnosis and treatment. Standard, forward-viewing endoscopy systems have a single imager so clinicians are switching to the Fuse system in an effort to improve the quality of their procedures.
Caption: The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from standard endoscopes. In clinical studies, the Fuse system identified 70% more polyps than traditional colonoscopies. Being able to see more anatomy may allow doctors to find more pre-cancerous polyps like the one in the right screen of this image.
The news from Health Canada enables EndoChoice to begin delivering Fuse endoscopy systems to their gastroenterology specialist customers throughout Canada.
“We intend to gain market clearance in several more countries in the near future,” said Mark Gilreath, Founder and CEO at EndoChoice®. “While 2013 has been an exciting year for our company, the introduction of Fuse into Canada and other markets will enable us to make 2014 even more dynamic as we bring this game-changing technology to more clinicians.”
Based in Atlanta, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy(TM) System (Fuse(TM)). 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com
EndoChoice® and Fuse(TM) are trademarks of EndoChoice®, Inc.
For more information, press only:
Doug Ladd, Chief Marketing Officer
513-608-6873 or Doug.Ladd@endochoice.com